Fierce Biotech: Regulus shares spike on a high success rate for RG-101 hep C combos

Can Regulus still make a splash in the increasingly crowded hepatitis C drug market? The biotech says yes, backing up its case for RG-101 with interim Phase II data that showed its injection pushed a small group of patients to a 97% sustained virologic response rate after only four weeks of combination therapies using some of the top oral drugs now on the market.

Read the full story at Fierce Biotech

Share This Article!